Nervous System DNase Delivery for cfDNA Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating neurodegenerative diseases associated with protein misfolding, particularly those caused by microbial and viral cell-free DNA, are limited in efficacy due to insufficient delivery of deoxyribonuclease enzymes across the blood-brain barrier, leading to inadequate clearance of misfolded proteins in the nervous system.
Innovation Solution
The use of nervous system-specific delivery vectors, such as recombinant adeno-associated virus (rAAV) and retroviral vectors, to express deoxyribonuclease enzymes within the nervous system, ensuring targeted and increased expression of DNase activity in the cerebrospinal fluid and neural tissues, thereby effectively clearing microbial and viral DNA and preventing protein misfolding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemic administration of high doses of DNase protein is used, then clearance of cfDNA in blood is improved, but delivery to nervous system remains insufficient
Solution Approach 1:
The invention segments the treatment approach by using different delivery routes for different targets: systemic administration for blood cfDNA clearance and direct nervous system delivery (intracerebroventricular or intrathecal) for CNS cfDNA clearance. This segmentation allows each route to optimize its effectiveness for the specific compartment it accesses.
Solution Approach 2:
The invention introduces delivery vehicles (viral vectors, liposomes, or protein formulations) as intermediaries to facilitate DNase delivery across the blood-brain barrier and into nervous system tissues. These intermediaries enable the DNase to reach its target in the CNS where it would otherwise be excluded by the blood-brain barrier.
2Quantity of substance
If systemic treatment with DNase protein is used, then blood cfDNA clearance is achieved, but efficacy against neurodegenerative diseases caused by microbial/viral DNA is limited
Solution Approach 1:
The treatment is segmented into two distinct components: systemic DNase administration for blood cfDNA clearance, and direct nervous system delivery of DNase for CNS cfDNA clearance. Both components are necessary to achieve comprehensive cfDNA reduction and treat neurodegenerative diseases, as each compartment (blood and CNS) requires targeted intervention.
Solution Approach 2:
The invention applies local quality by delivering DNase directly to the nervous system where microbial and viral cfDNA accumulate and cause protein misfolding. This localized delivery ensures high concentrations of DNase are present at the site of pathology, enabling effective clearance of pathogenic cfDNA that triggers neurodegenerative processes.
3Reliability
If direct nervous system delivery of DNase is implemented, then cfDNA clearance in CNS is improved, but treatment complexity increases
Solution Approach 1:
The invention uses delivery vehicles (viral vectors, liposomes, or formulated proteins) as intermediaries to simplify the complexity of direct nervous system delivery. These intermediaries protect the DNase from degradation, facilitate crossing of the blood-brain barrier, and enable sustained release, thereby reducing the operational complexity of achieving effective CNS delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach leads to significant anti-neurodegenerative effects and antitumor activities by almost completely clearing cell-free DNA from neural tissues and cerebrospinal fluid, providing neuroprotection and improving treatment outcomes for diseases triggered by microbial and viral DNA.
Implementation Method 1
an enzyme which has a deoxyribonuclease (DNase) activity
Data Source
AI summary
The invention relates to the nervous system-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of microbial and viral cell free DNA (cfDNA) accumulated in cerebrospinal fluid (CSF), brain and other parts of nervous system, with the use of such nervous-system specific delivery and/or expression for treatment of various diseases associated with protein misfolding.